Table 4 The sensitivity and specificity of combined IFITM1, CD10, h-caldesmon and SMA immunostaining in the diagnosis of endometrial stromal tumor
Groups | Sensitivity (%) | Specificity (%) |
|---|---|---|
IFITM1 (+) and h-caldesmon (−) for EST | 80.0 | 100.0 |
IFITM1 (+) and SMA (−) for EST | 60.0 | 97.0 |
CD10 (+) and h-caldesmon (−) for EST | 50.0 | 100.0 |
CD10 (+) and SMA (−) for EST | 36.7 | 100.0 |
IFITM1 (+) and CD10 (+) for EST | 56.7 | 93.9 |
IFITM1 (+) or CD10 (+) for EST | 93.3 | 66.7 |
IFITM1 (+) or CD10 (+) and h-caldesmon (−) for EST | 86.7 | 93.9 |
IFITM1 (+) and CD10 (+) and h-caldesmon (−) for EST | 53.3 | 100.0 |
IFITM1 (+) or CD10 (+) and SMA (−) for EST | 56.7 | 100.0 |
IFITM1 (+) and CD10 (+) and SMA (−) for EST | 30.0 | 100.0 |
IFITM1 (+) and CD10 (+) and h-caldesmon (−) and SMA (−) for EST | 31.0 | 100.0 |
IFITM1 (+) or CD10 (+) and h-caldesmon (−) and SMA (−) for EST | 56.7 | 100.0 |